Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03830151 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
A Phase 1 study of Primary Brain Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03830151: Recruiting Phase 1 study of Primary Brain Neoplasm, sponsored by M.D. Anderson Cancer Center.
NCT03830151 is a Phase 1 study of Primary Brain Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03830151, a Phase 1 study of Primary Brain Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI) scan may help researchers better diagnose glioma in patients with brain tumors.
Conditions Studied
Interventions
- DRUG Hyperpolarized Carbon C 13 Pyruvate
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03830151
The ClinicalTrials.gov registry entry for NCT03830151 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Brain Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Hyperpolarized Carbon C 13 Pyruvate is the first listed.
NCT03830151 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03830151 about?
NCT03830151 is a clinical study titled "Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors". This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI) scan may help researchers b...
What is the current status of trial NCT03830151?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-05-16. Estimated completion is 2028-12-31.
What conditions does trial NCT03830151 study?
This clinical trial studies the following conditions: Primary Brain Neoplasm.
What interventions are being tested in trial NCT03830151?
The interventions under investigation include: Hyperpolarized Carbon C 13 Pyruvate (DRUG), Magnetic Resonance Spectroscopic Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03830151?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03830151 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Brain Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.